GlassScriptPhysician profile
Megan Patterson
NPI 1164840112
$3,878.12
in general payments reported to CMS, 2019-2025
25 companies · $809 in 2025
The $809 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $77.94 · 2021: $729 · 2022: $577 · 2023: $702 · 2024: $983 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,405 · Education: $57.48 · Consulting Fee: $31.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,404.62 |
| Education | $57.48 |
| Consulting Fee | $31.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $537.69 | 2020-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $433.24 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $403.33 | 2021-2025 | Dupixent |
| Genentech USA, INC. | $386.57 | 2020-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $362.65 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Astrazeneca Pharmaceuticals LP | $339.10 | 2020-2025 | Tezspire, Fasenra, Airsupra |
| Ars Pharmaceuticals Operations, INC. | $244.17 | 2025 | Neffy |
| Grifols USA, LLC | $202.99 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Csl Behring | $161.15 | 2021-2025 | Hizentra, Andembry |
| Octapharma USA, INC. | $117.08 | 2021-2023 | Cutaquig |
| Biocryst US Sales Co., LLC | $101.46 | 2023-2025 | Orladeyo |
| Pfizer INC. | $96.48 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $92.02 | 2021-2025 | |
| Lilly USA, LLC | $84.56 | 2024-2025 | Ebglyss |
| Pharming Healthcare, INC. | $43.38 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $42.70 | 2021-2023 | |
| Amgen INC. | $39.75 | 2022-2023 | Tezspire |
| Greer Laboratories, INC. | $33.19 | 2023 | Oralair |
| Kaleo, INC. | $31.74 | 2022 | |
| Adma Biomanufacturing LLC | $31.72 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $26.05 | 2021 | |
| Merck Sharp & Dohme LLC | $20.97 | 2023 | |
| Bio Products Laboratory USA, INC. | $17.90 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.70 | 2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.